|
1
|
International Agency for Research on
Cancer (IARC): Latest global cancer data: Cancer burden rises to
19.3 million new cases and 10.0 million cancer deaths in 2020.
Questions and Answers (Q&A). https://www.iarc.who.int/faq/latest-global-cancer-data-2020-qa/.
Accessed January 10, 2021.
|
|
2
|
Zheng M: Classification and pathology of
lung cancer. Surg Oncol Clin N Am. 25:447–468. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ko B, Paucar D and Halmos B: EGFR T790M:
Revealing the secrets of a gatekeeper. Lung Cancer (Auckl).
8:147–159. 2017.
|
|
7
|
Shergold AL, Millar R and Nibbs RJ:
Understanding and overcoming the resistance of cancer to PD-1/PD-L1
blockade. Pharmacol Res. 145:1042582019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Regales L, Gong Y, Shen R, de Stanchina E,
Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O,
Mellinghoff IK, et al: Dual targeting of EGFR can overcome a major
drug resistance mutation in mouse models of EGFR mutant lung
cancer. J Clin Invest. 119:3000–3010. 2009.PubMed/NCBI
|
|
10
|
Oxnard GR, Yang JC, Yu H, Kim SW, Saka H,
Horn L, Goto K, Ohe Y, Mann H, Thress KS, et al: TATTON: A
multi-arm, phase Ib trial of osimertinib combined with selumetinib,
savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol.
31:507–516. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang JC, Shepherd FA, Kim DW, Lee GW, Lee
JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, et al: Osimertinib
plus durvalumab versus osimertinib monotherapy in EGFR
T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL
Brief Report. J Thorac Oncol. 14:933–939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Noble RL, Beer CT and Cutts JH: Role of
chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci.
76:882–894. 1958. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Rosenberg B: Platinum coordination
complexes in cancer chemotherapy. Naturwissenschaften. 60:399–406.
1973. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rowinsky EK and Donehower RC: Paclitaxel
(taxol). N Engl J Med. 332:1004–1014. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang H, Bai L, He J, Zhong L, Duan X,
Ouyang L, Zhu Y, Wang T, Zhang Y and Shi J: Recent advances in
discovery and development of natural products as source for
anti-Parkinson's disease lead compounds. Eur J Med Chem.
141:257–272. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ying J, Zhang M, Qiu X and Lu Y: The
potential of herb medicines in the treatment of esophageal cancer.
Biomed Pharmacother. 103:381–390. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Afanasenko A and Barta K: Pharmaceutically
relevant (hetero) cyclic compounds and natural products from
lignin-derived monomers: Present and perspectives. iScience.
24:1022112021. View Article : Google Scholar
|
|
19
|
Efferth T, Li PC, Konkimalla VS and Kaina
B: From traditional Chinese medicine to rational cancer therapy.
Trends Mol Med. 13:353–361. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szopa A, Ekiert R and Ekiert H: Current
knowledge of Schisandra chinensis (Turcz.) Baill. (Chinese magnolia
vine) as a medicinal plant species: A review on the bioactive
components, pharmacological properties, analytical and
biotechnological studies. Phytochem Rev. 16:195–218. 2017.
View Article : Google Scholar :
|
|
21
|
Wang J, Jiang B, Shan Y, Wang X, Lv X,
Mohamed J, Li H, Wang C, Chen J and Sun J: Metabolic mapping of
Schisandra chinensis lignans and their metabolites in rats using a
metabolomic approach based on HPLC with quadrupole time-of-flight
MS/MS spectrometry. J Sep Sci. 43:378–388. 2020. View Article : Google Scholar
|
|
22
|
Liu M, Zhao S, Wang Z, Wang Y, Liu T, Li
S, Wang C, Wang H and Tu P: Identification of metabolites of
deoxyschizandrin in rats by UPLC-Q-TOF-MS/MS based on multiple mass
defect filter data acquisition and multiple data processing
techniques. J Chromatogr B Analyt Technol Biomed Life Sci.
949-950:115–126. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu X, Cong L, Wang C, Li H, Zhang C, Guan
X, Liu P, Xie Y, Chen J and Sun J: Pharmacokinetics and
distribution of schisandrol A and its major metabolites in rats.
Xenobiotica. 49:322–331. 2019. View Article : Google Scholar
|
|
24
|
Jung KY, Lee IS, Oh SR, Kim DS and Lee HK:
Lignans with platelet activating factor antagonist activity from
Schisandra chinensis (Turcz.) Baill. Phytomedicine. 4:229–231.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo M and Lu Y, Yang J, Zhao X and Lu Y:
Inhibitory effects of Schisandra chinensis extract on acne-related
inflammation and UVB-induced photoageing. Pharm Biol. 54:2987–2994.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kwon DH, Cha HJ, Choi EO, Leem SH, Kim GY,
Moon SK, Chang YC, Yun SJ, Hwang HJ, Kim BW, et al: Schisandrin A
suppresses lipopolysaccharide-induced inflammation and oxidative
stress in RAW 264.7 macrophages by suppressing the NF-κB, MAPKs and
PI3K/Akt pathways and activating Nrf2/HO-1 signaling. Int J Mol
Med. 41:264–274. 2018.
|
|
27
|
Li S, Xie R, Jiang C and Liu M:
Schizandrin A alleviates LPS-induced injury in human keratinocyte
cell hacat through a MicroRNA-127-dependent regulation. Cell
Physiol Biochem. 49:2229–2239. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen DF, Zhang SX, Xie L, Xie JX, Chen K,
Kashiwada Y, Zhou BN, Wang P, Cosentino LM and Lee KH: Anti-AIDS
agents - XXVI. Structure-activity correlations of gomisin-G-related
anti-HIV lignans from Kadsura interior and of related synthetic
analogues. Bioorg Med Chem. 5:1715–1723. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ma WH, Lu Y, Huang H, Zhou P and Chen DF:
Schisanwilsonins A-G and related anti-HBV lignans from the fruits
of Schisandra wilsoniana. Bioorg Med Chem Lett. 19:4958–4962. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang M, Jin J, Sun H and Liu GT: Reversal
of P-glycoprotein-mediated multidrug resistance of cancer cells by
five schizandrins isolated from the Chinese herb Fructus
Schizandrae. Cancer Chemother Pharmacol. 62:1015–1026. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Min HY, Park EJ, Hong JY, Kang YJ, Kim SJ,
Chung HJ, Woo ER, Hung TM, Youn UJ, Kim YS, et al:
Antiproliferative effects of dibenzocyclooctadiene lignans isolated
from Schisandra chinensis in human cancer cells. Bioorg Med Chem
Lett. 18:523–526. 2008. View Article : Google Scholar
|
|
32
|
Moon PD, Jeong HJ and Kim HM: Effects of
schizandrin on the expression of thymic stromal lymphopoietin in
human mast cell line HMC-1. Life Sci. 91:384–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Park JH and Yoon J: Schizandrin inhibits
fibrosis and epithelial-mesenchymal transition in transforming
growth factor-β1-stimulated AML12 cells. Int Immunopharmacol.
25:276–284. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lin RD, Mao YW, Leu SJ, Huang CY and Lee
MH: The immuno-regulatory effects of Schisandra chinensis and its
constituents on human monocytic leukemia cells. Molecules.
16:4836–4849. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan H and Guo M: Schizandrin A inhibits
cellular phenotypes of breast cancer cells by repressing miR-155.
IUBMB Life. 72:1640–1648. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ji L and Ma L: MEG3 is restored by
schisandrin A and represses tumor growth in choriocarcinoma cells.
J Biochem Mol Toxicol. 34:e224552020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen BC, Tu SL, Zheng BA, Dong QJ, Wan ZA
and Dai QQ: Schizandrin A exhibits potent anticancer activity in
colorectal cancer cells by inhibiting heat shock factor 1. Biosci
Rep. 40:402020.
|
|
38
|
Xu X, Rajamanicham V, Xu S, Xu S, Liu Z,
Yan T, Liang G, Guo G, Zhou H, Wang Y, et al: Schisandrin A
inhibits triple negative breast cancer cells by regulating Wnt/ER
stress signaling pathway. Biomed Pharmacother. 115:1089222019.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ding Q, Li X, Sun Y and Zhang X:
Schizandrin A inhibits proliferation, migration and invasion of
thyroid cancer cell line TPC-1 by down regulation of microRNA-429.
Cancer Biomark. 24:497–508. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bi Y, Fu Y, Wang S, Chen X and Cai X:
Schizandrin A exerts anti-tumor effects on A375 cells by
down-regulating H19. Braz J Med Biol Res. 52:e83852019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee K, Ahn JH, Lee KT, Jang DS and Choi
JH: Deoxyschizandrin, isolated from Schisandra berries, induces
cell cycle arrest in ovarian cancer cells and inhibits the
protumoural activation of tumour-associated macrophages. Nutrients.
10:102018. View Article : Google Scholar
|
|
42
|
Kim SJ, Min HY, Lee EJ, Kim YS, Bae K,
Kang SS and Lee SK: Growth inhibition and cell cycle arrest in the
G0/G1 by schizandrin, a dibenzocyclooctadiene lignan isolated from
Schisandra chinensis, on T47D human breast cancer cells. Phytother
Res. 24:193–197. 2010. View Article : Google Scholar
|
|
43
|
Xian H, Feng W and Zhang J: Schizandrin A
enhances the efficacy of gefitinib by suppressing IKKβ/NF-κB
signaling in non-small cell lung cancer. Eur J Pharmacol.
855:10–19. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kong D, Zhang D, Chu X and Wang J:
Schizandrin A enhances chemosensitivity of colon carcinoma cells to
5-fluorouracil through up-regulation of miR-195. Biomed
Pharmacother. 99:176–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang ZL, Jiang QC and Wang SR:
Schisandrin A reverses doxorubicin-resistant human breast cancer
cell line by the inhibition of P65 and Stat3 phosphorylation.
Breast Cancer. 25:233–242. 2018. View Article : Google Scholar
|
|
46
|
Su X, Gao C, Shi F, Feng X, Liu L, Qu D
and Wang C: A micro-emulsion co-loaded with Schizandrin A-docetaxel
enhances esophageal carcinoma treatment through overcoming
multidrug resistance. Drug Deliv. 24:10–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
48
|
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko
TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, et al: A
common BIM deletion polymorphism mediates intrinsic resistance and
inferior responses to tyrosine kinase inhibitors in cancer. Nat
Med. 18:521–528. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Opletal L, Sovová H and Bártlová M:
Dibenzo[a, c]cyclooctadiene lignans of the genus Schisandra:
Importance, isolation and determination. J Chromatogr B Analyt
Technol Biomed Life Sci. 812:357–371. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zheng S, Aves SJ, Laraia L, Galloway WR,
Pike KG, Wu W and Spring DR: A concise total synthesis of
deoxyschizandrin and exploration of its antiproliferative effects
and those of structurally related derivatives. Chemistry.
18:3193–3198. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Newbold A, Martin BP, Cullinane C and Bots
M: Detection of apoptotic cells using propidium iodide staining.
Cold Spring Harb Protoc. 2014:1202–1206. 2014.PubMed/NCBI
|
|
52
|
Pan X, Zhao J, Zhang WN, Li HY, Mu R, Zhou
T, Zhang HY, Gong WL, Yu M, Man JH, et al: Induction of SOX4 by DNA
damage is critical for p53 stabilization and function. Proc Natl
Acad Sci USA. 106:3788–3793. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Santos JH, Hunakova L, Chen Y, Bortner C
and Van Houten B: Cell sorting experiments link persistent
mitochondrial DNA damage with loss of mitochondrial membrane
potential and apoptotic cell death. J Biol Chem. 278:1728–1734.
2003. View Article : Google Scholar
|
|
54
|
Yang Y, Karakhanova S, Hartwig W, D'Haese
JG, Philippov PP, Werner J and Bazhin AV: Mitochondria and
mitochondrial ROS in cancer: Novel targets for anticancer therapy.
J Cell Physiol. 231:2570–2581. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Chen M, Guerrero AD, Huang L, Shabier Z,
Pan M, Tan TH and Wang J: Caspase-9-induced mitochondrial
disruption through cleavage of anti-apoptotic BCL-2 family members.
J Biol Chem. 282:33888–33895. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Willis SN and Adams JM: Life in the
balance: How BH3-only proteins induce apoptosis. Curr Opin Cell
Biol. 17:617–625. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bouillet P, Zhang LC, Huang DC, et al:
Gene structure alternative splicing, and chromosomal localization
of pro-apoptotic Bcl-2 relative Bim. Mamm Genome. 12:163–168. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mauthe M, Orhon I, Rocchi C, Zhou X, Luhr
M, Hijlkema KJ, Coppes RP, Engedal N, Mari M and Reggiori F:
Chloroquine inhibits autophagic flux by decreasing
autophagosome-lysosome fusion. Autophagy. 14:1435–1455. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mauvezin C and Neufeld TP: Bafilomycin A1
disrupts autophagic flux by inhibiting both V-ATPase-dependent
acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome
fusion. Autophagy. 11:1437–1438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kim KH and Lee MS: Autophagy - a key
player in cellular and body metabolism. Nat Rev Endocrinol.
10:322–337. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Ha J, Guan KL and Kim J: AMPK and
autophagy in glucose/glycogen metabolism. Mol Aspects Med.
46:46–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Pasquier B: Autophagy inhibitors. Cell Mol
Life Sci. 73:985–1001. 2016. View Article : Google Scholar
|
|
63
|
Seebacher NA, Stacy AE, Porter GM and
Merlot AM: Clinical development of targeted and immune based
anti-cancer therapies. J Exp Clin Cancer Res. 38:1562019.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Keglevich P, Hazai L, Kalaus G and Szántay
C: Modifications on the basic skeletons of vinblastine and
vincristine. Molecules. 17:5893–5914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gaillard H, García-Muse T and Aguilera A:
Replication stress and cancer. Nat Rev Cancer. 15:276–289. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Cortez D: Replication-coupled DNA repair.
Mol Cell. 74:866–876. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Rehman SK, Haynes J, Collignon E, Brown
KR, Wang Y, Nixon AM, Bruce JP, Wintersinger JA, Singh Mer A, Lo
EB, et al: Colorectal cancer cells enter a Diapause-like DTP state
to survive chemotherapy. Cell. 184:226–242.e21. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Recasens A and Munoz L: Targeting cancer
cell dormancy. Trends Pharmacol Sci. 40:128–141. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Glick D, Barth S and Macleod KF:
Autophagy: Cellular and molecular mechanisms. J Pathol. 221:3–12.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye
WC, Zhang DM and Chen ZS: Autophagy and multidrug resistance in
cancer. Chin J Cancer. 36:522017. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Farrow JM, Yang JC and Evans CP: Autophagy
as a modulator and target in prostate cancer. Nat Rev Urol.
11:508–516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Liu G, Pei F, Yang F, Li L, Amin AD, Liu
S, Buchan JR and Cho WC: Role of autophagy and apoptosis in
non-small-cell lung cancer. Int J Mol Sci. 18:182017.
|
|
73
|
Piffoux M, Eriau E and Cassier PA:
Autophagy as a therapeutic target in pancreatic cancer. Br J
Cancer. 124:333–344. 2021. View Article : Google Scholar :
|
|
74
|
Zarzynska JM: The importance of autophagy
regulation in breast cancer development and treatment. BioMed Res
Int. 2014:7103452014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhou H, Yuan M, Yu Q, Zhou X, Min W and
Gao D: Autophagy regulation and its role in gastric cancer and
colorectal cancer. Cancer Biomark. 17:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hardie DG, Ross FA and Hawley SA: AMPK: A
nutrient and energy sensor that maintains energy homeostasis. Nat
Rev Mol Cell Biol. 13:251–262. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Lin SC and Hardie DG: AMPK: Sensing
Glucose as well as Cellular Energy Status. Cell Metab. 27:299–313.
2018. View Article : Google Scholar
|
|
78
|
Li Y and Chen Y: AMPK and autophagy. Adv
Exp Med Biol. 1206:85–108. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kimura T, Takabatake Y, Takahashi A and
Isaka Y: Chloroquine in cancer therapy: A double-edged sword of
autophagy. Cancer Res. 73:3–7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Wu YT, Tan HL, Shui G, Bauvy C, Huang Q,
Wenk MR, Ong CN, Codogno P and Shen HM: Dual role of
3-methyladenine in modulation of autophagy via different temporal
patterns of inhibition on class I and III phosphoinositide
3-kinase. J Biol Chem. 285:10850–10861. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Levy JMM, Towers CG and Thorburn A:
Targeting autophagy in cancer. Nat Rev Cancer. 17:528–542. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pesce E, Sondo E, Ferrera L, Tomati V,
Caci E, Scudieri P, Musante I, Renda M, Baatallah N, Servel N, et
al: The autophagy inhibitor Spautin-1 antagonizes rescue of mutant
CFTR through an autophagy-independent and USP13-mediated mechanism.
Front Pharmacol. 9:14642018. View Article : Google Scholar
|
